Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of an Oral Contraceptive with Chlormadinone Acetate on Depressive Mood

Analysis of Data from Four Observational Studies

Abstract

Background and objective:

Many women of reproductive age experience depressive mood symptoms such as sudden mood swings, irritability, nervousness, excitability and anxiety. Although not defined as a disease, these disturbing mental symptoms are associated with a considerable decrease in quality of life. Molecular pharmacology research over the last 20 years has shown that endogenous steroid hormones may interact with the CNS. Some of these hormones, i.e. the sex hormone progesterone and its 3α-reduced metabolites allopregnanolone (3α,5α-tetrahydroprogesterone) and epipregnanolone (3α,5β-tetrahydroprogesterone, eltanolone), influence mood-balancing and anxiolytic effects via the γ-aminobutyric acid receptor A (GABAA), a major inhibiting receptor of the CNS. Activation of GABAa receptor results in mood balancing, anxiolytic, antiepileptic and sedative actions. When oral contraception is considered, it should be taken into account that the various synthetic progestogens used may differ in their influence on mental state. For instance, there is strong clinical evidence of mood-balancing effects for the progesterone derivative chlormadinone acetate (CMA). The aim of these studies was to describe the clinical effects of CMA in combination with ethinylestradiol on depressive mood symptoms.

Methods:

Data from four prospective, non-interventional observational studies involving nearly 50 000 women were analysed. The studies documented use of four, six and 12 treatment cycles of the 28-day conventional regimen, as well as providing data on extended cycle regimens. The women in these studies were prescribed CMA 2 mg and ethinylestradiol (EE) 0.03 mg according to gynaecologists’ usual practice.

Results:

Clinical data from the studies confirmed that intake of CMA 2 mg and EE 0.03 mg promotes emotional well-being and reduces mood swings. Improvement in depressive mood was documented after four, six and 12 treatment cycles of the conventional intake regimen as well as with an extended-cycle regimen of CMA/EE.

Conclusion:

CMA 2 mg combined with EE 0.3 mg improves symptoms of depressive mood. The high structural congruence between the endogenous GABAa modulator epipregnanolone and the CMA metabolite M-V suggests a direct GABAergic, mood stabilizing function of CMA. We propose a theoretical concept — the CMA-GABAa model - that could explain the positive psychotropic effect of CMA.

This is a preview of subscription content, log in to check access.

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Data on file. Society for consumer goods research (Gesellschaft für Konsumgüterforschung). Survey on prevalence of depressive mood and other psychical disorders in German women. Dec 2005–Jan 2006

  2. 2.

    Smith SS. Female sex steroid hormones: from receptors to networks to performance — actions on the sensorimotor system. Progr Neurobiology 1994; 44: 55–86

  3. 3.

    Kuhl H. Depressive Verstimmungen und Steroidhormone des Ovars. Arch Gynecol Obstet 1997; 260: 515–28

  4. 4.

    Mok WM, Krieger NR. Evidence that 5 alpha-pregnan-3 alphaol-20-one is the metabolites responsible for progesterone anesthesia. Brain Res 1990; 533: 42–5

  5. 5.

    Monteleone P, Luisi S, Tonetti A, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000; 142: 269–73

  6. 6.

    Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709–14

  7. 7.

    Lovick TA. Plasticity of GABAa receptor subunit expression during the oestrus cycle of the rat: implications for premenstrual syndrome in women. Exp Physiol 2006; 91: 655–60

  8. 8.

    Slap GB. Oral contraceptives and depression: impact, prevalence and cause. J Adolesc Health Care 1981; 2: 53–64

  9. 9.

    Kendler KS, Martin NG, Heath AC, et al. A twin study of the psychiatric side effects of oral contraceptives. J Nerv Ment Dis 1988; 176: 153–60

  10. 10.

    Sanders SA, Graham CA, Bass JL, et al. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001; 64: 51–8

  11. 11.

    Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70: 229–40

  12. 12.

    Rapkin AJ, Morgan M, Sogliano C, et al. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes. Fertil Steril 2006 May; 85(5): 1371–8

  13. 13.

    Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med 1999; 61: 676–97

  14. 14.

    Genazzani AR, Stomati M, Morittu A, et al. Progesterone, progestogens and the central nervous system. Human Reproduction 2000; 15Suppl. 1: 14–27

  15. 15.

    Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28: 39–53

  16. 16.

    Sivin I. International experience with Norplant and Norplant-2 contraceptives. Stud Fam Plann 1988; 19: 81–94

  17. 17.

    Dougherty DM, Bjork JM, Moeller FG, et al. The influence of menstrual-cycle phase on the relationship between testosterone and aggression. Physiol Behav 1997; 62: 431–5

  18. 18.

    Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception 2007; 76(2): 84–90

  19. 19.

    Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara®). Clin Drug Invest 2002; 22(4): 221–31

  20. 20.

    Bock K, Heskamp ML, Schramm G. Influence of chlormadinone acetate on dysmenorrhoea and other cycle-related complaints [in German]. Gyne 2008; 8: 219–25

  21. 21.

    Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara®: efficacy, tolerability and anti-androgenic properties. Contraception 2003 Apr; 67(4): 305–12

  22. 22.

    Stomati M, Bersi C, Rubino S, et al. Neuroendocrine effects of different oestradiol-progestin regimens in postmenopausal women. Maturitas 1997; 28: 127–35

  23. 23.

    Stomati M, Bernardi F, Luisi S, et al. Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and beta-endorphin. Maturitas 2002; 43: 195–206

  24. 24.

    Luine VN, McEwen BS. Effect of oestradiol on turnover of type A monoamine oxidase in brain. J Neurochem 1977; 28:1221–7

  25. 25.

    Zarate A, Fonseca E, Ochoa R, et al. Low-dose conjugated equine estrogens elevate circulating neurotransmitters and improve the psychological well-being of menopausal women. Fertil Steril 2002; 77: 952–5

  26. 26.

    Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003; 28: 139–68

  27. 27.

    Lenzi E, Begliuomini S, Pluchino M, et al. Effect of chlormadinone acetate administration on central and peripheral allopregnanolone in OVX rats. Gynecol Endocrinol 2008; 24Suppl. 1: OP227

  28. 28.

    Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABA(A) receptors. J Neuroendocrinol 1995; 7: 171–7

  29. 29.

    Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986; 232: 1004–7

  30. 30.

    Akwa Y, Purdy R, Koob G, et al. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res 1999; 106: 119–25

  31. 31.

    Mehta AK, Ticku MK. An update on GABAa receptors. Brain Res Rev 1999; 29: 196-217

  32. 32.

    Macdonald R, Olsen RW. GABAa receptor channels. Ann Rev Neurosci 1994; 17: 569–602

  33. 33.

    Zinder O, Dar DE. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol Scand 1999; 167: 181–8

  34. 34.

    Bernardi F, Pluchino N, Begliuomini S, et al. Disadaptive disorders in women: allopregnanolone, a sensitive steroid. Gynecol Endocrinol 2004; 19: 344–53

  35. 35.

    Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAa receptor. Mechanism of action and physiological significance. Prog Neurobiol 1992; 38: 379–95

Download references

Acknowledgements

All four non-interventional studies presented in this paper were conducted and sponsored by Grünenthal GmbH, Germany. The authors would like to thank all gynaecologists who participated in these observational studies. In addition, the authors would like to thank all the Clinical Research Organisations (PPD, Nürnberg; Institut Dr. Schauerte, Grünwald; Factum GmbH, Offenbach; Pharm-Soft Dr. B. Rodust GmbH, Ascheberg; Germany) who performed the analysis and reporting. Drs Heskamp and Schramm are employees of Grünenthal GmbH. Prof. Huber has no conflicts of interest that are directly relevant to the content of this study.

Author information

Correspondence to Prof. Dr Dr Johannes C. Huber.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Huber, J.C., Heskamp, M.S. & Schramm, G.A.K. Effect of an Oral Contraceptive with Chlormadinone Acetate on Depressive Mood. Clin. Drug Investig. 28, 783–791 (2008). https://doi.org/10.2165/0044011-200828120-00006

Download citation

Keywords

  • Depressive Mood
  • GABAA Receptor
  • Allopregnanolone
  • Dienogest
  • Estradiol Valerate